Quantum Molecular Resonance to Treat Neuropathic Corneal Pain and Regrow Corneal Nerves
Efficacy of Quantum Molecular Resonance in Neuropathic Corneal Pain and Corneal Nerve Regeneration
This study will try Quantum Molecular Resonance (QMR) to reduce eye pain and promote corneal nerve regrowth in adults with neuropathic corneal pain.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 21 Years and up |
| Sex | All |
| Sponsor | Singapore Eye Research Institute Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Singapore) |
| Trial ID | NCT07174739 on ClinicalTrials.gov |
What this trial studies
Adults with neuropathic corneal pain will attend nine visits including one baseline assessment and eight QMR treatment sessions using a Rexon-Eye device. At each visit participants will undergo ocular surface exams, in vivo confocal microscopy to measure corneal nerve morphology, tear protein collection, and symptom and quality-of-life questionnaires. Investigators will compare pain scores, corneal nerve metrics, ocular surface findings, and tear biomarkers before and after the QMR treatment course. The study team hypothesizes that repeated QMR sessions will reduce pain, stimulate corneal nerve regeneration, and improve patient-reported quality of life.
Who should consider this trial
Good fit: Adults aged 21 and older with diagnosed neuropathic corneal pain, minimal slit-lamp findings, and corneal nerve abnormalities on IVCM who can attend all study visits are ideal candidates.
Not a fit: Patients who are pregnant, have active implantable electronic devices, recent ocular surgery, active ocular infection or inflammation, or are undergoing cancer treatment are excluded and unlikely to benefit from participation.
Why it matters
Potential benefit: If successful, QMR could reduce chronic eye pain, improve corneal nerve structure, and enhance daily functioning and quality of life for affected patients.
How similar studies have performed: Small studies of QMR/Rexon-Eye in dry eye populations have reported symptom improvements, but rigorous evidence for use in neuropathic corneal pain is limited and relatively untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Be at least 21 years of age. * Regardless of gender (Male/Female). * Regardless of race (Chinese/Malay/Indian/Eurasian/Others). * Diagnosed with neuropathic corneal pain based on the following criteria: presence of neuropathic ocular symptoms (burning, stinging, photophobia, pain, severe dryness), absent or minimal slit-lamp findings to explain the symptoms and corneal nerve abnormalities as detected by IVCM (decreased corneal length and density, presence of neuromas). * Willing to receive all eye examinations in this study. Exclusion Criteria: * Pregnant women. * Participants carrying active implantable devices (e.g., pacemakers and hearing aids). * Oncologic patients under treatment; patient who underwent ocular surgery in the last month. * Participants who had ocular infection within 6 months, or active ocular infection or inflammation; any concomitant ocular diseases that could potentially induce ocular pain, such as uveitis.
Where this trial is running
Singapore
- Singapore National Eye Centre — Singapore, Singapore (Recruiting)
Study contacts
- Study coordinator: Yu-Chi Liu, MD, MCI, PhD
- Email: liu.yu.chi@snec.com.sg
- Phone: 65 65767287
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.